| Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma. | endometrial, |
| The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay. | kidney, |
| GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma. | glioma, |
| Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. | colorectal, |
| strong inter-relation between DR4 AND DR5 overexpression and presence of oncogenic KRAS/ BRAF mutations in colon cancer. | colorectal, |
| Ovarian surface epithelial cells resist the oncogenic insults of Kras/Pten by robust self-protecting mechanisms that silence the Kras gene and elevate PTEN and phosphorylated p38 MAPK. | ovarian, |
| Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. | leukemia, |
| Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia. | leukemia, |
| Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer , and this may potentially contribute to the phenotypic differences of KRAS and BRAF mutations in colon tumors. | colorectal, |
| Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. | pancreatic, |
| BRAF and KRAS oncogenes have different transforming capability in colon cancer | colorectal, |
| BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. | colorectal, |
| Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. | colorectal, |
| Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. | colorectal, |
| Oncogene expression in the liver tissue of patients with nonneoplastic liver disease. | liver, |
| Establishment of a sarcoma cell line, MS-K, expressing Ki-ras proto-oncogene product from mouse bone marrow stromal cells. | sarcoma, |
| A mouse model of melanoma driven by oncogenic KRAS. | skin, |
| data establish that oncogenic KRAS can be a founder event in melanomagenesis. | skin, |
| Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. | colorectal, |
| SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. | colorectal, |